linjc16/ctgov huggingface dataset:
Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the efficacy of blood restriction therapy by comparing increase in muscle mass and strength in patients that receive blood restriction therapy to patients who receive a placebo.

Official Title
-----------------
Blood Flow Restriction Therapy in Patellofemoral Pain Syndrome

Conditions
-----------------
Patellofemoral Pain Syndrome

Intervention / Treatment
-----------------
* Procedure: Placebo
* Procedure: Personalized Tourniquet System for Blood Flow Restriction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA class I-II Diagnosed with patellofemoral pain syndrome Exclusion Criteria: Patients with confirmed radiographic evidence explaining knee pain Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia, etc.) Younger than 18 years of age or older than 65 Any patient considered a vulnerable subject Patients with impaired circulation, peripheral vascular compromise, Previous revascularization of the extremity, or severe hypertension Patients with Sickle cell anemia or venous thromboembolism Patients with Sickle cell anemia or venous thromboembolism Patients with cancer or Lymphectomies Patients with increased intracranial pressure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients with Patellopain syndrome with Cuff<br>Patient will be prescribed to 6 weeks of physical therapy with a cuff around the affected leg during exercises | Procedure: Personalized Tourniquet System for Blood Flow Restriction<br>* Patients will be receiving blood flow restriction therapy with a pressure cuff<br>|
| Placebo Comparator: Patients with Patellopain syndrome with Placebo Cuff<br> | Procedure: Placebo<br>* Patients will be receiving blood flow restriction therapy with a pressure cuff set to a placebo pressure setting.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increase in Muscle Mass Measured by Biodex | Biodex dynamometer is used under standard of care to measure the extensor strength of both legs and have bilateral thigh circumference measured | 6 Weeks | 
| Decrease in Pain measured by Visual Analog Scale (VAS) | 100-mm horizontal line anchored at one end with the words no pain and at the other end with the words worst pain imaginable. | 6 Weeks |
The Effect of Alcohol on ABCA1 Expression and Lipid Metabolism

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effects of red wine on ABCA1 levels

Conditions
-----------------
Type 2 Diabetes, Heart Disease

Intervention / Treatment
-----------------
* Dietary Supplement: Red Wine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy participants Aged 18-65 years Free of overt coronary disease BMI < 35 Fasting plasma glucose <6.1 mmol Unmedicated No major illness Exclusion Criteria: Unable to give informed consent Smokers Participants with alcoholism

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Dietary Supplement: Red Wine|20g alcohol daily/red wine for 4 weeks|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurements of dyslipidemia |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lipid functionality |  | 2 years |
Implementation of an Enhanced Rehabilitation Protocol After Liver Transplantation: Feasibility and Analysis of Results

Study Overview
=================
Brief Summary
-----------------
Currently, there are no expert recommendations regarding enhanced rehabilitation after liver transplantation. The development of Enhanced Rehabilitation After Surgery (ERAS) protocols in major surgery, particularly cardiothoracic surgery, has motivated some anesthesia teams to extubate liver transplant patients earlier who meet predefined criteria (young patient, absence of comorbidities, absence of intraoperative transfusion) in order to limit the occurrence of complications of mechanical ventilation (pneumopathies, tracheal wound, muscle loss, etc.) On the other hand, improved rehabilitation in this case was often synonymous with early extubation in the operating room. Few studies, on the other hand, relate the implementation of a complete rehabilitation protocol including pre-, intra- and postoperative guidelines.

Official Title
-----------------
Implementation of an Enhanced Rehabilitation Protocol After Liver Transplantation: Feasibility and Analysis of Results

Conditions
-----------------
Liver Transplant Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Major subject operated at HUS for a liver transplant whose management was scheduled in the Surgical Intensive Care Unit fbetween December 01, 2018 and August 31, 2020 Subject who does not question, after information, the reuse of his data for the purpose of this research Exclusion criteria: Subject having expressed his opposition to participate in the study Liver transplant patient hospitalized in the Medical Intensive Care Unit before or after the surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective description of the protocol of improved rehabilitation after liver transplantation, to study the possibility of its implementation in the anesthesia-intensive care department and to analyze the first results |  | Files analysed retrospectively from December 01, 2018 to August 31, 2020 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver Transplant Disorder, Liver transplantation, ERAS
Validation of a Production Method of Stem Cell Isolated From the Nasal Cavity for an Innovative Cell Therapy of Cleft Palate

Study Overview
=================
Brief Summary
-----------------
Cell therapy appears to be an alternative to treat bone defects. Scientific advances have shown in animal models and in humans that mesenchymal stem cells were good candidates to support cellular bone regeneration after transplantation. However, their collection requires invasive sampling usually bone marrow. A new candidate stem cells able to stimulate bone regeneration has recently been identified in the nasal cavity, these cells are called ecto-mesenchymal cells. These stem cells have very similar biological characteristics of mesenchymal stem cells of bone marrow. They exhibit a high mitogenic activity and hold great potential for differentiation into osteoblast lineage. Given their properties and their ease of access within the nasal cavity, ecto-mesenchymal stem cells offer new prospects for cell therapy targeting bone involvement. In this context, the ecto-mesenchymal stem cells represent a nasal bone reconstruction interesting alternative in particular in indication of the cleft. They are directly and easily accessible in these children when conventional surgical reconstruction. The investigators propose in this study to validate a production method of stem cell called ecto-mesenchymal isolated from a biopsy of the nasal cavity of children with cleft lip and palate to be able to soon propose cell therapy innovative in this indication.

Conditions
-----------------
Cleft Palate

Intervention / Treatment
-----------------
* Procedure: sampling mesenchymal stem cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Paediatric patients with unilateral cleft lip and alveolar (or maxilla) or labio-maxillo-palatal, requiring surgical management of reconstruction Children weighing more than 2 kg Exclusion Criteria: Children with concomitant pathology that might alter bone turnover: osteogenesis imperfecta, kidney failure, chronic inflammatory diseases, infections, other diseases

Ages Eligible for Study
-----------------
Maximum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Children with cleft<br> | Procedure: sampling mesenchymal stem cells<br>* nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of nasal mesenchymental stem cells |  | 12 months |
Fitness Trackers During and After Oncological Treatments

Study Overview
=================
Brief Summary
-----------------
The overall goal of the present trial is to evaluate the patients' compliance for wearing a commercially available fitness tracker during and after oncological treatments.

Official Title
-----------------
Pilot Study for the Continuous Assessment of Biological Parameters Using a Fitness Tracker Before, During and After Radiochemotherapy or Chemotherapy in Patients With Oncological Diseases

Conditions
-----------------
Cancer, Physical Activity, Fatigue

Intervention / Treatment
-----------------
* Device: Fitness Tracker


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed malignant disease Upcoming chemotherapy of radiochemotherapy Eastern Co-operative Oncology Group (ECOG) performance score 0-2 Exclusion Criteria: Pre-existing comorbidities that impair patient mobility. Eastern Co-operative Oncology Group (ECOG) performance score 3-4

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fitness tracker Arm<br>Patients will be wearing a commercially available fitness tracker during radiotherapy or chemotherapy and four weeks after the end of treatment. | Device: Fitness Tracker<br>* Patients will continuously wear a commercially available fitness tracker which will collect data on physical activity (steps), pulse rate and sleep behaviour.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compliance for wearing the fitness tracker | Based on the read outs from the fitness trackers we will calculate the percentage of the days on which the tracker was worn, which is defined as the compliance. | Four weeks after the end of radiotherapy |
GF-GS 01: Comparing Conventional Axillary Dissection Versus Sentinel Node Resection in Clinically Node-negative Operable Breast Cancer

Study Overview
=================
Brief Summary
-----------------
Sentinel node resection appears as a promising advancement in the surgical treatment of breast cancer. The GF-GS 01 study, sponsored by a National Hospital Research Program, compares this new surgical method with a classical method in patients having a negative sentinel node. The duration of the follow-up is 5 years.

Official Title
-----------------
A Randomized, Phase III Clinical Trial GF-GS 01 to Compare Conventional Axillary Dissection Versus Sentinel Node Resection (GS) in Clinically Node-negative Operable Breast Cancer Unifocal N0 Patients

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Procedure: Sentinel Node Resection
* Procedure: Conventional Axillary Dissection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women older than 18 years with clinically node-negative operable unifocal N0 breast cancer (clinical tumour size < 30 mm). Written consent is obtained from all patients before randomization.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sentinel Node Resection<br>Sentinel Node Resection | Procedure: Sentinel Node Resection<br>* Sentinel Node Resection<br>|
| Other: Conventional Axillary Dissection<br>Conventional Axillary Dissection | Procedure: Conventional Axillary Dissection<br>* Conventional Axillary Dissection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival without recurrence |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Breast cancer, sentinel node resection, survival, Breast cancer unifocal N0
Acetabular Cerclage and Total Hip Arthroplasty in the Treatment of Acetabular Fractures in Elderly Patients.

Study Overview
=================
Brief Summary
-----------------
We want to present the outcome of complex multifragmented acetabular fractures in the elderly treated with acetabular cerclage and total hip arthroplasty.

Official Title
-----------------
Acetabular Cerclage and Total Hip Arthroplasty in the Treatment of Acetabular Fractures in Elderly Patients.

Conditions
-----------------
Cerclage Acetabular Fractures, Total Hip Arthroplasty, Elderly, Acetabular Fractures

Intervention / Treatment
-----------------
* Device: Cerclage and total hip arthroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: elderly (>60Years) acetabular fracture Exclusion Criteria: Revision surgery

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| THA + cerclage acetabulum<br> | Device: Cerclage and total hip arthroplasty<br>* acetabular fractures in the elderly treated with cerclage acetabulum and total hip arthroplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| harris hip score | outcome after cerclage and THA | 1 year |
Effect of Arterial Cannulation on the Continuous and Non-invasive Hemoglobin Monitoring

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to investigate the effect of arterial cannulation on the continuous and non-invasive hemoglobin monitoring during laparoscopic gastrectomy

Official Title
-----------------
Effect of Arterial Cannulation on the Continuous and Non-invasive Hemoglobin Monitoring for Laparoscopic Gastrectomy

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Other: arterila cannulation on same arm
* Other: arterila cannulation on different arm


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Laparoscopic gastrectomy under general anesthesia Exclusion Criteria: atypical hemoglobin disease, infective state, cardiovascular disease, peripheral vascular disease

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Same group<br>arterial cannulation on same arm of continuous hemoglobin monitoring | Other: arterila cannulation on same arm<br>* arterila cannulation on same arm receiving continous hemoglobin monitoring<br>|
| Placebo Comparator: Different group<br>arterial cannulation on different arm of continuous hemoglobin monitoring | Other: arterila cannulation on different arm<br>* arterila cannulation different arm receiving continous hemoglobin monitoring<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference between SpHb value and SaHb value (SpHb - SaHb) in g/dL | SpHb value (g/dL) is measured by co-oxymetry, and SaHb value (g/dL) is measured by blood sampling. | 3 time points from the start of anesthesia to the end of anesthesia, an average 2 hours |
Evaluation of Streptococcus Pneumoniae Serotypes Prevalence Using a Urinary Kit

Study Overview
=================
Brief Summary
-----------------
This is an epidemiology study for the prevalence and serotypes of pneumococcus pneumoniae in hospitalized patients with community acquired pneumonia (CAP). The serotypes of the pneumococcus pneumoniae will be determined by a urinary antigen assay. This is a single center, non-interventional observatory study.

Detailed Description
-----------------
Patients admitted to the medical wards with a provisional diagnosis under pneumonia,chest infection or fever will be screened by research assistants. Patients eligible with the inclusion criteria will be recruited into the study. Informed consent will be signed for those patients willing to participate in the study. Patient will be asked to save approximately 40 ml of urine. The urine sample will be processed in local laboratory and shipped out to a commercial lab for detection of any pneumococcal pneumoniae, and if present, serotyping will be performed at the same time using the same urine sample by urinary antigen assay. Meanwhile patients will be managed as usual by their clinical teams. Investigations and treatment will be offered by the clinical team as deemed necessary. The study team will only perform collection of urine and will not interfere the clinical management of the patients. Positive results would be informed to the clinical teams for the appropriate action.

Official Title
-----------------
Prospective Study to Evaluate Streptococcus Pneumoniae Serotypes Prevalence in Community Acquired Pneumonia in Hong Kong Using a Urinary Kit

Conditions
-----------------
Community-acquired Pneumonia

Intervention / Treatment
-----------------
* Diagnostic Test: urine test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted with signs and symptoms suggestive of pneumonia Exclusion Criteria: 1. Nosocomial pneumonia which is acquired >= 48 hours after hospital admission. 2. Pneumonia which are already known to be caused by pathogens other than pneumococcus pneumoniae.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CAP<br>community acquired pneumonia | Diagnostic Test: urine test<br>* test for pneumococcal antigen in urine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the prevalence of pneumococcal serotypes in adults hospitalized | Determine the prevalence of pneumococcal serotypes in adults hospitalized with pneumococcal community acquired pneumonia (CAP) using a specific urine antigen assay | 2 years |
Effect of Acute Treatment With N2O on Inhibitory Pain Mechanisms in Healthy Subject

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether N2O (laughing gas) has an antinociceptive effects in healthy volunteers.

Detailed Description
-----------------
10 healthy volunteers will come twice to the pain medicine unit, at 1 visit they'll get N2O and in the second visit they'll get air as placebo, they won't know what they're getting. During the visit they'll get heat stimulus using QST and will have to report their pain using eVAS (scale from 0 to 100 when 0 is no pain and 100 is the worst pain imagine).

Official Title
-----------------
Effect of Acute Treatment With N2O on Inhibitory Pain Mechanisms in Healthy Subject

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: N2O
* Drug: Air


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-50 years old women and men healthy Exclusion Criteria: smokers medication use pregnant woman cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: N2O<br>N20 70% inhalation 5 minutes O2 100 % inhalation for 5 minutes | Drug: N2O<br> <br> * Other names: laughing gas;|
| Sham Comparator: Air<br> | Drug: Air<br>* sham comparator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain Scores on the Visual Analog Scale |  | August 2016 |